IKT revenueQ2 2026$0
- FY YoY
- -100.0%
IKT revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2024 it was $0, down 100.0% from fiscal 2023.
Inhibikase Therapeutics Inc. (IKT) financials
For the twelve months ended Jun 30, 2026, Inhibikase Therapeutics Inc. reported -$60.64M of net income.
- Net income, TTM
- -$60.64M
- Free cash flow, TTM
- -$42.61M
- EPS, diluted, TTM
- -$0.44
- Cash
- $31.21M
- Market cap
- $208.6M
FY2020FY2024
FY2020FY2025
FY2021FY2025
IKT revenue and earnings growth
IKT net incomeQ2 2026-$19.59M
IKT net income was -$19.59M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$9.92M a year earlier. For the full fiscal 2025 it was -$48.26M, compared with -$27.52M in fiscal 2024.
IKT EPSQ2 2026-$0.11
IKT diluted EPS was -$0.11 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.49.
IKT free cash flowQ2 2026-$12.44M
IKT free cash flow was -$12.44M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.57M a year earlier. For the full fiscal 2025 it was -$27.80M, compared with -$19.15M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $0 | $260.5K | $123.4K | $3.10M | $698.5K |
| Research and development | $29.79M | $17.21M | $13.62M | $12.03M | $11.36M | $893.8K |
| Selling, general and admin | $23.56M | $11.38M | $6.73M | $6.22M | $6.51M | $2.62M |
| Operating income | -$51.97M | -$28.59M | -$20.09M | -$18.13M | -$14.77M | -$2.82M |
| Interest expense | - | - | - | - | $19.9K | $29.4K |
| Pre-tax income | -$48.3K | -$27.5K | - | - | - | - |
| Income tax | $0 | $0 | - | - | - | - |
| Net income | -$48.26M | -$27.52M | -$19.03M | -$18.05M | -$14.79M | -$2.85M |
| EPS, basic | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$4.86 | -$2.10 |
| EPS, diluted | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$4.86 | -$2.10 |
| Diluted shares | 98.3M | 23.7M | 6.0M | 4.2M | 3.0M | 1.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $139.22M | $56.49M | $9.17M | $7.19M | $40.75M | $13.95M |
| Short-term investments | $39.54M | $41.05M | $4.09M | $15.86M | $0 | - |
| Current assets | $180.11M | $98.45M | $14.21M | $24.37M | $42.47M | $14.78M |
| Total assets | $181.20M | $98.60M | $14.51M | $24.94M | $42.47M | $14.78M |
| Current liabilities | $8.30M | $3.73M | $3.44M | $3.70M | $4.05M | $4.72M |
| Total debt | - | $0 | $381.8K | $0 | $248.9K | $319.0K |
| Total liabilities | $8.30M | $3.73M | $3.53M | $3.90M | $4.05M | $5.00M |
| Shareholders' equity | $172.90M | $94.87M | $10.98M | $21.04M | $38.42M | $9.78M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$27.79M | -$19.15M | -$18.09M | -$17.35M | -$14.30M | -$1.13M |
| Capital expenditures | $13.4K | $0 | $14.2K | $243.3K | $0 | - |
| Free cash flow | -$27.80M | -$19.15M | -$18.10M | -$17.59M | -$14.30M | - |
| Investing cash flow | $2.05M | -$37.00M | $11.66M | -$16.01M | $0 | - |
| Financing cash flow | $108.46M | $103.48M | $8.41M | -$204.8K | $41.09M | $15.06M |
| Stock-based compensation | $15.31M | $8.14M | $500.1K | $458.1K | $1.53M | $573.7K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | 111.0% | -96.0% | 343.9% | - |
| Operating margin | - | - | -7712.0% | -14686.2% | -476.2% | -403.5% |
| Net margin | - | - | -7304.7% | -14625.9% | -476.9% | -407.7% |
| Free cash flow margin | - | - | -6947.9% | -14253.4% | -461.1% | - |
| Return on equity | -27.9% | -29.0% | -173.3% | -85.8% | -38.5% | -29.1% |
| Return on assets | -26.6% | -27.9% | -131.2% | -72.4% | -34.8% | -19.3% |
| Current ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | 3.13 |
| Debt to equity | - | 0.00 | 0.03 | 0.00 | 0.01 | 0.03 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 | $79.6K |
| Research and development | $13.39M | $10.84M | $6.36M | $7.65M | $5.27M | $10.51M | $7.19M | $4.19M | $3.08M | $2.75M | $3.00M | $3.23M |
| Selling, general and admin | $7.66M | $7.38M | $6.77M | $5.61M | $5.92M | $5.25M | $5.74M | $1.64M | $1.97M | $2.03M | $1.40M | $1.62M |
| Operating income | -$21.05M | -$17.84M | -$13.78M | -$12.77M | -$10.83M | -$14.60M | -$12.93M | -$5.83M | -$5.05M | -$4.78M | -$4.40M | -$4.77M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | $0 |
| Net income | -$19.59M | -$16.38M | -$12.73M | -$11.93M | -$9.92M | -$13.68M | -$12.13M | -$5.78M | -$4.96M | -$4.65M | -$4.18M | -$4.60M |
| EPS, basic | -$0.11 | -$0.10 | -$0.10 | -$0.13 | -$0.11 | -$0.15 | - | -$0.65 | -$0.66 | -$0.73 | - | -$0.86 |
| EPS, diluted | -$0.11 | -$0.10 | -$0.10 | -$0.13 | -$0.11 | -$0.15 | - | -$0.65 | -$0.66 | -$0.73 | - | -$0.86 |
| Diluted shares | 174.6M | 172.3M | - | 90.1M | 90.0M | 89.5M | - | 8.9M | 7.5M | 6.3M | - | 5.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $31.21M | $49.57M | $139.22M | $38.27M | $77.74M | $73.44M | $56.49M | $913.4K | $3.09M | $2.35M | $9.17M | $14.86M |
| Short-term investments | $127.81M | $120.80M | $39.54M | $39.05M | $9.92M | $19.74M | $41.05M | $2.33M | $4.85M | $7.40M | $4.09M | $1.97M |
| Current assets | $162.34M | $172.18M | $180.11M | $78.54M | $88.79M | $94.16M | $98.45M | $4.19M | $8.60M | $10.81M | $14.21M | $17.55M |
| Total assets | $163.59M | $173.33M | $181.20M | $79.59M | $88.85M | $94.28M | $98.60M | $4.38M | $8.83M | $11.07M | $14.51M | $17.88M |
| Current liabilities | $10.26M | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M | $4.91M | $3.70M | $4.23M | $3.44M | $2.74M |
| Total debt | - | - | - | - | - | - | $0 | - | - | - | $381.8K | - |
| Total liabilities | $10.26M | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M | $4.91M | $3.73M | $4.29M | $3.53M | $2.86M |
| Shareholders' equity | $153.33M | $167.62M | $172.90M | $72.90M | $80.05M | $85.73M | $94.87M | -$530.6K | $5.10M | $6.78M | $10.98M | $15.02M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.44M | -$12.06M | -$7.52M | -$10.59M | -$5.57M | -$4.10M | -$5.35M | -$4.88M | -$5.05M | -$3.87M | -$3.44M | -$4.11M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $13.4K | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$12.44M | -$12.06M | -$7.52M | -$10.59M | -$5.57M | -$4.12M | -$5.35M | -$4.88M | -$5.05M | -$3.87M | -$3.44M | -$4.11M |
| Investing cash flow | -$5.91M | -$80.48M | -$98.8K | -$28.75M | $9.84M | $21.05M | -$38.76M | $2.53M | $2.54M | -$3.31M | -$2.12M | $17.06M |
| Financing cash flow | -$14.5K | $2.90M | $108.57M | -$134.1K | $31.8K | $0 | $99.68M | $182.0K | $3.24M | $367.0K | -$138.1K | $70 |
| Stock-based compensation | $5.35M | $5.56M | $4.53M | $4.53M | $4.21M | $2.04M | $7.91M | $148.0K | $30.7K | $53.4K | $122.2K | $129.8K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | 991.3% |
| Operating margin | - | - | - | - | - | - | - | - | - | - | -440356600.0% | -5993.4% |
| Net margin | - | - | - | - | - | - | - | - | - | - | -417794000.0% | -5775.1% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - | -344243100.0% | -5159.2% |
| Current ratio | 15.82 | 30.14 | 21.70 | 11.73 | 10.09 | 11.01 | 26.37 | 0.85 | 2.32 | 2.55 | 4.13 | 6.40 |
| Debt to equity | - | - | - | - | - | - | 0.00 | - | - | - | 0.03 | - |
Source: XBRL data Inhibikase Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-6, first reported Aug 14, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
IKT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IKT | - | - | -$60.64M | - | $208.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
IKT FAQ
7 questionsIs IKT profitable?
No. Inhibikase Therapeutics Inc. reported a net loss of $60.64M for the twelve months ended Jun 30, 2026.How much cash and debt does IKT have?
Inhibikase Therapeutics Inc. reported $31.21M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is IKT revenue growing?
Inhibikase Therapeutics Inc.'s revenue changed -100.0% in fiscal 2024, to $0.What is IKT free cash flow?
Inhibikase Therapeutics Inc. generated -$42.61M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$42.61M less capital expenditures.What is IKT earnings per share?
Diluted earnings per share were -$0.44 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did IKT last report financial results?
The latest statements here come from Inhibikase Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this IKT financial data come from?
Quantisnow builds these statements from the structured XBRL data Inhibikase Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.